Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties
Open Access
- 1 December 2017
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 5 (6)
- https://doi.org/10.1002/prp2.370
Abstract
Sphingosine-1-phosphate receptor 1 (S1P1) modulators sequester circulating lymphocytes within lymph nodes, thereby preventing potentially pathogenic autoimmune cells from exiting into the blood stream and reaching inflamed tissues. S1P1 receptor modulation may thus offer potential to treat various autoimmune diseases. The first nonselective S1P1-5 receptor modulator FTY720/fingolimod/Gilenya® has successfully demonstrated clinical efficacy in relapsing forms of multiple sclerosis. However, cardiovascular, hepatic, and respiratory side-effects were reported and there is a need for novel S1P1 receptor modulators with better safety profiles. Here, we describe the discovery of cenerimod, a novel, potent and selective S1P1 receptor modulator with unique S1P1 receptor signaling properties and absence of broncho- and vasoconstrictor effects ex vivo and in vivo. Cenerimod dose-dependently lowered circulating lymphocyte counts in rats and mice after oral administration and effectively attenuated disease parameters in a mouse experimental autoimmune encephalitis (EAE) model. Cenerimod has potential as novel therapy with improved safety profile for autoimmune diseases with high unmet medical need.Keywords
This publication has 36 references indexed in Scilit:
- Amelioration of Collagen-Induced Arthritis by a Novel S1P1 Antagonist with Immunomodulatory ActivitiesPublished by The American Association of Immunologists ,2012
- Impact of sphingosine 1-phosphate modulation on immune outcomesNeurology, 2011
- Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric FunctionJournal of Pharmacology and Experimental Therapeutics, 2010
- 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1Receptor AgonistsJournal of Medicinal Chemistry, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Analysis of sphingosine 1‐phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological toolsBritish Journal of Pharmacology, 2008
- Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cellsProstaglandins & Other Lipid Mediators, 2004
- Sphingosine‐1‐phosphate stimulates contraction of human airway smooth muscle cellsThe FASEB Journal, 2003
- The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate ReceptorsPublished by Elsevier BV ,2002
- Sphingosine 1‐phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthmaThe FASEB Journal, 2001